Latest News

Senior scientist Dr Mike Gresser, with experience at Amgen and Merck will assist the drive to develop new personalised medicines.

Monogram announces 20 presentations related to its portfolio of HIV diagnostic assays at the 14th Annual Conference on Retroviruses and Opportunistic Infections.

Lipomics seeks to partner with academic institutions and drug companies to advance its goal of developing diagnostic tests for metabolic diseases.

FDA has approved the first phase of a BG Medicine and National Center for Toxicological Research project to discover biomarkers of human hepatotoxicity in the standard pre-clinical test.

Both Companies in collaboration have developed a platform for customers in the diagnostics industry to test solutions based on Magnisense's MIAtek™ technology.

Galapagos' service division to provide lead optimization services for a University of Bristol research program focusing on destroying cancer cells in a contract valuing €2 million over two years.

Agilent will combine its analytical platforms with Lipomics’ expertise in biomarker discovery and validation to develop assays for metabolic diseases.

CytoCore notes a market report projecting 41 percent annual growth in the area of molecular diagnostics and screening in the United States alone, with a market potential of $92 billion projected by 2016.

Argos Therapeutics initiates a Phase 1/2 clinical trial to test the immunologic activity and safety of its AGS-004 in HIV-infected adults.

Swiss-based computational biology provider Genedata AG announced a three-year expansion of their collaboration with the HepatoSys research network.